Tracer library / [225Ac]Ac-hu5A10

[225Ac]Ac-hu5A10

Also written as [Ac-225]hu5A10

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Prostate cancer Preclinical only, no clinical indication yet

What it is

Compound class: Humanized monoclonal antibody (IgG1)
Target / mechanism: Targets free PSA (KLK3) PMID 33441295
Clinical application: Radioimmunotherapy of prostate cancer using alpha-emitting 225Ac-labeled anti-PSA antibody PMID 33441295
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	—	—	hu5A10 DiaProst AB / Innovagen AB	33441295 2021 Clin Cancer Res The hu5A10 radio-immunoconstructs were prepared according to previously published protocols unique to the specific radionuclide (see supplementary methods).

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: DiaProst AB / Innovagen AB
Typical final purification: —

Need this precursor?We can point you to suppliers for [225Ac]Ac-hu5A10, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 33441295. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 33441295: 'Humanized 5A10 IgG1 mAb was developed by DiaProst AB (Lund, Sweden) and produced by Innovagen AB (Lund, Sweden)'.